Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Proctor & Gamble Pharma Extend RNAi Pact Through 2006

This article corrects an earlier version that contained inaccurate information. The original said the agreement runs through 2008.

 

NEW YORK, Nov. 2 (GenomeWeb News) - Invitrogen and Proctor & Gamble Pharmaceuticals have extended a research service agreement through 2006, the firms said today.

 

The agreement extends a collaboration between the two companies that is several years old.

 

According to Invitrogen's CEO Greg Lucier, P&GP has been using Invitrogen's RNAi tools such as Stealth, RNAi Gateway, and lentiviral vectors in its target-identification and -validation programs.

 

Financial details were not discussed.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.